Search clinical trials for: Lu AF28996 solution

Total 19710 results

H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (STARBEAM)

Alzheimer's Disease

United States, Argentina, Brazil, Canada, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Taiwan, United Kingdom, Ireland
AHS Cancer Control Alberta
Cross Cancer Institute

Active, not recruiting

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Neuroendocrine Tumors, NET

Canada
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT)

Alzheimer's Disease

United States, Australia, Brazil, Czechia, Germany, Israel, Korea, Republic of, Mexico, Serbia, Singapore, Slovakia, Spain, Switzerland, Turkey, United Kingdom
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Pheochromocytoma | Paraganglioma | Gastroenteropancreatic Neuroendocrine Tumors

United States, Spain, France, Poland, United Kingdom
Tine Gregersen, MD

Recruiting

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients (DOBATOC)

Neuroendocrine Neoplasm

Denmark
National Cancer Centre, Singapore
Novartis; Advanced Accelerator Applications

Recruiting

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in (SG-AAA-II-01)

Metastatic Nasopharyngeal Cancer

Singapore
H. Lundbeck A/S

Completed

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Healthy

Denmark
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Progenics...

Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3)

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor

United States
Jules Bordet Institute

Completed

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN)

Gastroenteropancreatic Neuroendocrine Tumors

Belgium
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
University of California, Davis
National Institutes of Health (NIH)

Recruiting

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Metastatic Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma

Spain, Switzerland, France, Portugal, United States
Baskent University

Unknown

Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery

Myocardial Injury

Turkey
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation; Paul Scherrer Institute (PSI)

Recruiting

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

Neuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Switzerland
Radboud University Medical Center

Completed

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

Netherlands
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
ORA, Inc.
Palatin Technologies, Inc

Completed

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Dry Eye Disease

United States
H. Lundbeck A/S

Completed

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Schizophrenia | Cognition

Hong Kong, Thailand, Belgium, France, Germany, Italy, Poland, Taiwan
Washington University School of Medicine
Quest Medical, Inc

Recruiting

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

Aortic Valve Disease | Mitral Valve Disease

United States
HanAll BioPharma Co., Ltd.

Completed

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (VELOS-1)

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Medical University of Vienna

Recruiting

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Prostate Cancer

Austria
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
VivaVision Biotech, Inc

Not yet recruiting

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

Dry Eye

China
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Dry Eye Disease

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes | Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
University of California, Davis
United States Department of Defense

Recruiting

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Metastatic Nonsmall Cell Lung Cancer

United States
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Meiji Seika Pharma Co., Ltd.

Completed

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Onychomycosis

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada

Search clinical trials for: Lu AF28996 solution

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations